Thymosin β4 sustained release from poly(lactide-co-glycolide) microspheres: synthesis and implications for treatment of myocardial ischemia

Ann N Y Acad Sci. 2012 Oct:1270:112-9. doi: 10.1111/j.1749-6632.2012.06681.x.

Abstract

A sustained release formulation for the therapeutic peptide thymosin β4 (Tβ4) that can be localized to the heart and reduce the concentration and frequency of dose is being explored as a means to improve its delivery in humans. This review contains concepts involved in the delivery of peptides to the heart and the synthesis of polymer microspheres for the sustained release of peptides, including Tβ4. Initial results of poly(lactic-co-glycolic acid) microspheres synthesized with specific tolerances for intramyocardial injection that demonstrate the encapsulation and release of Tβ4 from double-emulsion microspheres are also presented.

Publication types

  • Review

MeSH terms

  • Humans
  • Lactic Acid / chemistry*
  • Microspheres
  • Myocardial Ischemia / drug therapy*
  • Polyglycolic Acid / chemistry*
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Thymosin / administration & dosage
  • Thymosin / chemistry*
  • Thymosin / therapeutic use*

Substances

  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
  • thymosin beta(4)
  • Thymosin